Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Vabysmo faricimab Diabetic Macular Edema Reimburse with clinical criteria and/or conditions Complete
Vabysmo faricimab Macular degeneration, age-related Reimburse with clinical criteria and/or conditions Complete
Vabysmo faricimab Retinal vein occlusion Active
Vanflyta quizartinib acute myeloid leukemia (AML) Pending
Vantas Histrelin acetate Cancer, prostate Do not list Complete
Vascepa icosapent ethyl Ischemic events in statin-treated patients Reimburse with clinical criteria and/or conditions Complete
Vectibix Panitumumab Left Sided Metastatic Colorectal Cancer (mCRC) Do not reimburse Complete
Vectibix Panitumumab Metastatic Colorectal Cancer Reimburse with clinical criteria and/or conditions Complete
Veklury remdesivir COVID-19 in hospitalized patients Reimburse with clinical criteria and/or conditions Active
Veklury remdesivir COVID-19 in non-hospitalized patients Reimburse with clinical criteria and/or conditions Active